Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 7Phase 1/2 4Phase 3 3Phase 4 1Phase 2/3 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 4Uveal Melanoma 2Neoplasm Metastasis 2Prostatic Neoplasms 1Lung Neoplasms 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced or Metastatic Solid Malignancies 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 6Pemetrexed 5Carboplatin 5pembrolizumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Docetaxel 4Gemcitabine 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cemiplimab 2auricularum 2Specimen Handling 2Ramucirumab 2Radiotherapy 2Leucovorin 2Erlotinib Hydrochloride 2Drug Therapy 2Calcium Dobesilate 2pertuzumab 1oblimersen 1maimendongtang 1endostar protein 1cyclopropapyrroloindole 1cediranib 1aumolertinib 1anamorelin 1Vitamin B 12 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lung Neoplasms × Ipilimumab × Clear all
NCT04929041 2026-05-13

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

National Cancer Institute (NCI)

Phase 2/3 Suspended
427 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡